NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/19/2026
Back to search
Official data from USPTO
LIQUID BIOPSY IS REVOLUTIONIZING CANCER TREATMENT. NRICHDX EMPOWERS THAT REVOLUTION.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LIQUID BIOPSY IS REVOLUTIONIZING CANCER TREATMENT. NRICHDX EMPOWERS THAT REVOLUTION.
ST13
US500000088250571Class
10
Filing
88250571
Registration
6190469
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
02/20/2026
Trademark type
Word
Nice classes
10
Filing date
01/04/2019
Registration date
11/03/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/19/2026
Last transaction
02/20/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/01/2018
First use in commerce
02/10/2020
Drawing code
4
Owner type
03
Owner location
IRVINE, CA, US
Examiner
RIRIE, VERNA BETH
Current location
Historical data usage
Holders and representatives
Holders
WAVESENSE, INC.
Representatives
Matthew A. Newboles Stetina Garred Brucker & Newboles
Technical classification
Nice Classes
Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 10
cell culture and cancer diagnostics testsliquid biopsy testing systems consisting of a specimen chamber assembly and magnetic materials used to sequester target analytes of interest within a liquid sample for isolation and characterization
Publications
History of USPTO decisions and trademark events.
28 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
02/19/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/19/2026
E815
TEAS SECTION 8 & 15 RECEIVED
11/14/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/03/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
11/03/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/02/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/01/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/18/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/18/2020
IUAF
USE AMENDMENT FILED
09/02/2020
EISU
TEAS STATEMENT OF USE RECEIVED
09/02/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/04/2020
EX2G
SOU EXTENSION 2 GRANTED
07/02/2020
EXT2
SOU EXTENSION 2 FILED
07/02/2020
EEXT
SOU TEAS EXTENSION RECEIVED
07/02/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/31/2019
EX1G
SOU EXTENSION 1 GRANTED
12/27/2019
EXT1
SOU EXTENSION 1 FILED
12/27/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/27/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/02/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/07/2019
PUBO
PUBLISHED FOR OPPOSITION
05/07/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/17/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/22/2019
DOCK
ASSIGNED TO EXAMINER
03/21/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/26/2019
NWAP
NEW APPLICATION ENTERED
01/08/2019
Continuous trademark protection
Get notified about every new filing that threatens LIQUID BIOPSY IS REVOLUTIONIZING CANCER TREATMENT. NRICHDX EMPOWERS THAT REVOLUTION. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.